SEC Form	4
----------	---

Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287	
	Estimated average bure	den	
Filed purpuent to Section 16(a) of the Securities Evolution Act of 1024	hours per response:	0.5	

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Barone Francesca (Last) (First) (Middle) C/O CANDEL THERAPEUTICS, INC. 117 KENDRICK ST., SUITE 450		g Person [*]	2. Issuer Name and Ticker or Trading Symbol Candel Therapeutics, Inc. [CADL]		ationship of Reporting P < all applicable) Director	erson(s) to Issuer 10% Owner			
		()	3. Date of Earliest Transaction (Month/Day/Year) 11/26/2023	X	Officer (give title below) Chief Scientifi	Other (specify below) c Officer			
		E 450	4. If Amendment, Date of Original Filed (Month/Day/Year)	Line)	,				
(Street) NEEDHAM	MA	02494		X	Form filed by More the Person				
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication						
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								
		Table I - Non-De	erivative Securities Acquired. Disposed of. or Ben	eficially	v Owned				

140												
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		Disposed Of (Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	v	Amount (A) or Price		Transaction(s) (Instr. 3 and 4)		(1150.4)			
Common Stock	11/26/2023		Α		112,790 ⁽¹⁾	A	\$0.00	206,405	D			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Transaction O Code (Instr. D 8) A (/ D 0 (I		Transaction of Code (Instr. Derivative		of Expiration Date // Derivative (Month/Day/Year) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					

Explanation of Responses:

1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. 50% of the RSUs shall vest on June 30, 2024, and the remaining 50% on December 31, 2024, in each case subject to the Reporting Person's continued service on such vesting date.

Remarks:

/s/ Jason Amello, as Attorney-11/28/2023 in-Fact for Francesca Barone

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.